An early trial of an experimental coronavirus vaccine from Pfizer Inc. and BioNtech SE showed positive results, Pfizer announced.
The experimental vaccine was tested on 45 healthy adults divided into several groups: 24 of them got two injections with two different doses, 12 of them received a single shot with a very high dose, and nine patients got two dummy injections. Preliminary data released by the company states the groups that got two shots had 'significantly elevated' antibodies within four weeks of their first injection.
BioNTech, the first European company to release vaccine trial results, is using messenger RNA (mRNA) technology to develop a vaccine — a process that is faster than traditional methods. The study of Pfizer's and BioNtech's vaccine candidate is undergoing scientific peer review. The companies are studying at least four experimental vaccines at various doses. The ones that show the most promising results will undergo the next stage of tests, which may start as early as this month and involve as many as 30,000 patients.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.